Dianthus Therapeutics (STU:87E) Other Current Liabilities: €2.34 Mil (As of Mar. 2026)


STU:87E Dianthus Therapeutics Inc STU:87E
22 GF Score
Price €82.00
GF Value €2.53
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Dianthus Therapeutics Other Current Liabilities?

Dianthus Therapeutics STU:87E 22 Other Current Liabilities is €2.34 Mil as of Mar. 2026. GuruFocus rates STU:87E with a GF Score™ of 22/100 and a GF Value™ of €2.53 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Dianthus Therapeutics's other current liabilities for the quarter that ended in Mar. 2026 was €2.34 Mil.

Dianthus Therapeutics's quarterly other current liabilities increased from Sep. 2025 (€5.68 Mil) to Dec. 2025 (€8.13 Mil) but then declined from Dec. 2025 (€8.13 Mil) to Mar. 2026 (€2.34 Mil).

Dianthus Therapeutics's annual other current liabilities increased from Dec. 2023 (€4.92 Mil) to Dec. 2024 (€4.92 Mil) and increased from Dec. 2024 (€4.92 Mil) to Dec. 2025 (€8.13 Mil).

Dianthus Therapeutics Other Current Liabilities Related Terms

Dianthus Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Dianthus Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dianthus Therapeutics Other Current Liabilities Chart

Dianthus Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
0.18 1.97 4.92 4.92 8.13

Dianthus Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.90 3.30 5.68 8.13 2.34
STU:87E
22GF Score
Dianthus Therapeutics Inc STU:87E
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dianthus Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €2.34 Mil mean?
Dianthus Therapeutics (STU:87E) has a Other Current Liabilities of €2.34 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Dianthus Therapeutics.
Is Dianthus Therapeutics' Other Current Liabilities too high?
Dianthus Therapeutics' current Other Current Liabilities is €2.34 Mil. Overall, Dianthus Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dianthus Therapeutics' Other Current Liabilities compare to CAI and TNGX?
Dianthus Therapeutics' Other Current Liabilities of €2.34 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Dianthus Therapeutics. Dianthus Therapeutics's current Other Current Liabilities is €2.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dianthus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Dianthus Therapeutics (STU:87E) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.53, compared to a current price of €82.00 — trading 3141.1% above its estimated fair value. The current Other Current Liabilities is €2.34 Mil. Dianthus Therapeutics' overall GF Score™ is 22/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Dianthus Therapeutics (STU:87E), the current Other Current Liabilities is €2.34 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dianthus Therapeutics (STU:87E) Overvalued in 2026?

Based on GuruFocus' analysis, Dianthus Therapeutics stock appears to be overvalued. The current stock price of €82.00 is trading 3141.1% above its estimated GF Value™ of €2.53. GuruFocus considers Dianthus Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:87E:

  • Other Current Liabilities: €2.34 Mil
  • GF Value™: €2.53 vs. price of €82.00 (3141.1% above fair value)
  • GF Score™: 22/100 with 7 warning signs

No single metric tells the full story. See the STU:87E stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dianthus Therapeutics Business Description

Other Exchanges DNTH:USA
Address 7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
22GF Score

Get the complete analysis for STU:87E

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€82.00
Price
€2.53
GF Value